Markus Müschen, MD, PhD
Research & Publications
Biography
News
Locations
Research Summary
To prevent production of harmful autoantibodies and autoimmune disease, autoreactive B-cells are eliminated by a process termed negative selection. In recent years, our laboratory established new conceptual frameworks for the understanding of B-cell signaling mechanisms and negative selection. Contrary to established dogma, these mechanisms are not only active in preventing autoimmune disease but also represent an emerging class of therapeutic targets in malignant B-cell tumors.
- We discovered regulation of energy-abundance as the central determinant of negative B-cell-selection: Hyperactivation of kinases downstream of an autoreactive B-cell receptor induces ATP-depletion and energy stress.
- Studying changes of energy-metabolism during B-cell transformation, we discovered that glucose carbon-flux was diverted in way that left transformed B-cells uniquely vulnerable to inhibition of PP2A, an enzyme that coordinates glycolytic flux with antioxidant protection.
- We discovered that changes in cell-size are orchestrated by BCL6 and MYC. Opposed by MYC, BCL6 decreases cell-size by transcriptionally repressing glucose-uptake in favor of autophagy.
- Tracking mechanisms of leukemia-initiation in 1,100 patients, we developed the paradigm of ‘pathway convergence’. Only mutations that converged on one central pathway promoted leukemia-progression. Genetic reactivation of divergent (suppressed) pathways engaged conflicting biochemical and transcriptional programs and subverted leukemia-development. Pharmacological pathway-reactivation to create a diverse signaling-environment represents a novel strategy to prevent leukemia-progression.
- Studying biophysical mechanisms of B-cell activation, we discovered the short endosomal protein IFITM3 as central scaffold for lipid-raft assembly and surface-expression of rafts-associated receptors. Membrane-recruitment of IFITM3 was essential for the initiation of PI3K-signaling, antibody affinity maturation and oncogenic B-cell transformation.
- Drug discovery tool for selective targeting of B-cell malignancies: We developed an interactive computational tool (lymphoblasts.org) to identify novel B-cell selective vulnerabilities based on integrated genetic and pharmacological compound screens. Compound screening data from CTD and GDSC databases were reprocessed by fitting 4-parameter log-logistic dose response curves. Differential gene-dependency was also tested using DEMETER2 and Chronos scores, from Project Achilles RNAi and CRISPR datasets, respectively. To prioritize cell-type specific targets, compounds were ranked by average differential rank percentile of both compound-sensitivity and target-gene dependency.
Extensive Research Description
Since 2009, the Müschen laboratory has established new conceptual frameworks for the understanding of B-cell signaling and energy metabolism and how defects in these mechanisms contribute to autoimmunity and B-cell transformation. Influenced by his postdoctoral training in basic immunology (Klaus Rajewsky and Ralf Küppers) and cancer genetics (Janet D. Rowley), Dr. Müschen is particularly interested in signal transduction pathways that change the clinical trajectory of human B-cell malignancies and B-cell driven autoimmune diseases. To generate hypotheses and for target discovery, his laboratory builds on clinical outcome predictors: in collaboration with multiple study teams across the US, his group developed and validated phenotypic biomarkers of favorable and poor clinical outcomes in B-cell malignancies and integrated these markers into models of oncogenic signaling pathways. As PI of the NCI CTEP ‘Human hematopoiesis and leukemia PDX’ program, his laboratory developed PDX resources to model B-cell malignancies based on patient-derived cells and cord blood-based humanized mouse models to study mechanisms of human B-lymphopoiesis in vivo.
In 2010, Dr. Müschen joined the University of California San Francisco (UCSF) as full professor with tenure and served as Program Leader of the Hematological Malignancies Program at the UCSF Comprehensive Cancer Center. He is currently a Howard Hughes Medical Institute (HHMI) Faculty Scholar and supported by an NCI Outstanding Investigator Award (R35). The Müschen laboratory consists of 18 trainees and staff. So far, 16 of his former trainees have become tenured or tenure-track faculty in academic research at institutions including UCSF, Imperial College, University of Pennsylvania, Stanford University, WEHI, TU Munich, SIBS Shanghai, Penn State and University of Cologne. At Yale University, Dr. Müschen serves as Director of the Center of Molecular and Cellular Oncology and as a mentor for six junior faculty.
Coauthors
Research Interests
Antibody Affinity; Antibody Specificity; Arthritis, Rheumatoid; Autoimmune Diseases; Autophagy; B-Lymphocytes; Burkitt Lymphoma; Cell Adhesion; Cell Communication; Cell Cycle; Cell Division; DNA Damage; Endocytosis; Energy Metabolism; Genes, Immunoglobulin; Hematologic Diseases; Hodgkin Disease; Immunity; Immunologic Deficiency Syndromes; Leukemia; Leukemia, Hairy Cell; Lupus Nephritis; Lymphocyte Cooperation; Lymphocyte Activation; Lymphoma; Lymphoma, Follicular; Lymphomatoid Granulomatosis; Metabolism; Mycosis Fungoides; Oxygen Consumption; Phosphorylation; Preleukemia; Receptor Aggregation; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell; Sjogren's Syndrome; Gene Rearrangement; Signal Transduction; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Prolymphocytic, T-Cell; Leukemia, Prolymphocytic; Lymphoma, B-Cell; Lymphoma, T-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Lymphoma, AIDS-Related; Cellular Senescence; Cell Death; Lymphoma, Large-Cell, Anaplastic; Lymphomatoid Papulosis; Antigen Presentation; Oxidative Stress; Lymphoma, B-Cell, Marginal Zone; Molecular Mimicry; Cell Respiration; Cell Lineage; Lymphoma, Mantle-Cell; Lupus Vasculitis, Central Nervous System; Cell Size; Carbohydrate Metabolism; Lipid Metabolism; Genes, Immunoglobulin Heavy Chain; Activating Transcription Factors; Leukemia, Large Granular Lymphocytic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Leukemia, Prolymphocytic, B-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, Primary Effusion; Metabolome; Rheumatoid Vasculitis; Autoimmune Lymphoproliferative Syndrome; Enteropathy-Associated T-Cell Lymphoma; Composite Lymphoma; Wnt Signaling Pathway; Clonal Evolution; Clonal Selection, Antigen-Mediated; Immunoreceptor Tyrosine-Based Activation Motif; Optogenetics; Cellular Reprogramming; Plasmablastic Lymphoma; Oncogene Addiction; Cell Competition
Public Health Interests
Biomarkers; Cancer; Clinical Trials; Evolution; Genetics, Genomics, Epigenetics; Immunology; Metabolism; Metabolomics
Selected Publications
- Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 AxisLi M, Yang L, Chan A, Pokharel S, Liu Q, Mattson N, Xu X, Chang W, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan L, Lee J, Zhang X, Rosen S, Müschen M, Qi J, Chen J, Hiom K, Bishop A, Chen C. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis Advanced Science 2023, 10: 2206584. PMID: 37075745, PMCID: PMC10265057, DOI: 10.1002/advs.202206584.
- Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemiaOgana H, Hurwitz S, Hsieh C, Geng H, Müschen M, Bhojwani D, Wolf M, Larocque J, Lieber M, Kim Y. Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia Frontiers In Cell And Developmental Biology 2023, 11: 1134121. PMID: 37082620, PMCID: PMC10111164, DOI: 10.3389/fcell.2023.1134121.
- Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemiaChen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen L, Zhang Z, Prince E, Weng H, Huang H, Zhao Z, Qing Y, Shen C, Li W, Han L, Tan B, Su R, Qin H, Li Y, Wu D, Gu Z, Ngo V, He X, Chao J, Leung K, Wang K, Dong L, Qin X, Cai Z, Sheng Y, Chen Y, Wu X, Zhang B, Shi Y, Marcucci G, Qian Z, Xu M, Müschen M, Chen J, Deng X. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia Science Translational Medicine 2023, 15: eabq8513. PMID: 36989375, DOI: 10.1126/scitranslmed.abq8513.
- Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasmsTaghi Khani A, Kumar A, Sanchez Ortiz A, Radecki K, Aramburo S, Lee S, Hu Z, Damirchi B, Lorenson M, Wu X, Gu Z, Stohl W, Sanz I, Meffre E, Müschen M, Forman S, Koff J, Walker A, Swaminathan S. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms Communications Biology 2023, 6: 295. PMID: 36941341, PMCID: PMC10027679, DOI: 10.1038/s42003-023-04667-8.
- Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signalingFeng X, Sun R, Lee M, Chen X, Guo S, Geng H, Müschen M, Choi J, Pereira J. Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling ELife 2023, 12: e83533. PMID: 36912771, PMCID: PMC10042536, DOI: 10.7554/elife.83533.
- ACTR5 controls CDKN2A and tumor progression in an INO80-independent mannerXu X, Chan A, Li M, Liu Q, Mattson N, Pokharel S, Chang W, Yuan Y, Wang J, Moore R, Pirrotte P, Wu J, Su R, Müschen M, Rosen S, Chen J, Yang L, Chen C. ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner Science Advances 2022, 8: eadc8911. PMID: 36563143, PMCID: PMC9788768, DOI: 10.1126/sciadv.adc8911.
- Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery 2022, 4: 8-11. PMID: 36534735, PMCID: PMC9816816, DOI: 10.1158/2643-3230.bcd-22-0180.
- Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human LymphopoiesisCosgun K, Liu W, Robinson M, Fonseca Arce D, VanOudenhove J, Bigogno A, Flavell R, Halene S, Müschen M. Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human Lymphopoiesis Blood 2022, 140: 8744-8745. DOI: 10.1182/blood-2022-170409.
- BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell TransformationChan L, Hurtz C, Robinson M, Leveille E, Geng H, Caeser R, Xu L, Kume K, Xiao G, Müschen M. BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation Blood 2022, 140: 9177-9178. DOI: 10.1182/blood-2022-169946.
- GSK3β Inhibition Is a Unique Vulnerability in Lymphoid MalignanciesCosgun K, Jumaa H, Robinson M, Chan L, Lee J, Kume K, Fonseca Arce D, Jellusova J, Müschen M. GSK3β Inhibition Is a Unique Vulnerability in Lymphoid Malignancies Blood 2022, 140: 3114-3115. DOI: 10.1182/blood-2022-169961.
- A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell SignalingLee J, Kume K, Robinson M, Sun R, Ma N, Chen Z, Xiao G, Cosgun K, Chan L, Leveille E, Klemm L, Vykunta V, Shy B, Geng H, Luger S, Litzow M, Marson A, Paietta E, Vaidehi N, Meffre E, Müschen M. A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling Blood 2022, 140: 1698-1699. DOI: 10.1182/blood-2022-170324.
- Divergent MYC- and BCL6-Driven Metabolic Programs Enable Dynamic Regulation of Cell Biomass in B-Cell MalignanciesKume K, Chen Z, Chan L, Robinson M, Leveille E, Lee J, Cosgun K, Fonseca Arce D, Khanduja D, Klemm L, Müschen M. Divergent MYC- and BCL6-Driven Metabolic Programs Enable Dynamic Regulation of Cell Biomass in B-Cell Malignancies Blood 2022, 140: 5900-5901. DOI: 10.1182/blood-2022-170396.
- Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL ProgressionBrandmeier L, Ecker V, Stumpf M, Giansanti P, Varela Moreira A, Pfeuffer L, Fens M, Lu J, Küster B, Engleitner T, Heidegger S, Ringshausen I, Zenz T, Wendtner C, Müschen M, Ruland J, Buchner M. Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression Blood 2022, 140: 9840-9841. DOI: 10.1182/blood-2022-160103.
- Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic LeukemiaChen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen L, Zhang Z, Prince E, Weng H, Huang H, Zhao Z, Qing Y, Shen C, Han L, Tan B, Li W, Su R, Qin H, Li Y, Wu D, Gu Z, Ngo V, He X, Chao J, Leung K, Wang K, Dong L, Qin X, Cai Z, Sheng Y, Chen Y, Wu X, Zhang B, Shi Y, Marcucci G, Qian Z, Xu M, Müschen M, Deng X, Chen J. Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia Blood 2022, 140: 998-1000. DOI: 10.1182/blood-2022-165469.
- SYK and ZAP70 kinases in autoimmunity and lymphoid malignanciesLeveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies Cellular Signalling 2022, 94: 110331. PMID: 35398488, DOI: 10.1016/j.cellsig.2022.110331.
- Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell TransformationChan L, Hurtz C, Leveille E, Kume K, Robinson M, Geng H, Cosgun K, Müschen M. Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation Blood 2021, 138: 792-792. DOI: 10.1182/blood-2021-148653.
- Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid MalignanciesLee J, Robinson M, Ma N, Kume K, Artadji D, Sadras T, Cosgun K, Geng H, Paietta E, Buchner M, Vaidehi N, Weinstock D, Müschen M. Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies Blood 2021, 138: 355-355. DOI: 10.1182/blood-2021-149189.
- Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell TransformationLee J, Robinson M, Ma N, Sadras T, Cosgun K, Chan L, Kume K, Thomas-Tikhonenko A, Weinstock D, Diamond M, Vaidehi N, Müschen M. Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation Blood 2021, 138: 868-868. DOI: 10.1182/blood-2021-149646.
- Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic LeukemiaChan L, Murakami M, Hurtz C, Kume K, Lee J, Cosgun K, Geng H, Izraeli S, Weinstock D, Müschen M. Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood 2021, 138: 616-616. DOI: 10.1182/blood-2021-149773.
- Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinal Center B-Cell MalignanciesKume K, Lee J, Chan L, Robinson M, Cosgun K, Meffre E, Müschen M. Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinal Center B-Cell Malignancies Blood 2021, 138: 2267-2267. DOI: 10.1182/blood-2021-149806.
- Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell MalignanciesCosgun K, Robinson M, Chan L, Hur M, Leveille E, Song J, Chan W, Müschen M. Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell Malignancies Blood 2021, 138: 29-29. DOI: 10.1182/blood-2021-148597.
- Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung CancerMirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer Molecular Cancer Therapeutics 2021, 20: 1820-1835. PMID: 34253596, PMCID: PMC8722383, DOI: 10.1158/1535-7163.mct-21-0013.
- Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunitiesXu L, Chen Y, Huang Y, Sandanaraj E, Yu J, Lin R, Dakle P, Ke X, Chong Y, Koh L, Mayakonda A, Nacro K, Hill J, Huang M, Gery S, Lim S, Huang Z, Xu Y, Chen J, Bai L, Wang S, Wakimoto H, Yeo T, Ang B, Müschen M, Tang C, Tan T, Koeffler P. Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities Cancer Research 2021, 81: 2123-2123. DOI: 10.1158/1538-7445.am2021-2123.
- Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancerSadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan WC, Meffre E, Martin T, Müschen M. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer Molecular Cell 2021, 81: 2094-2111.e9. PMID: 33878293, PMCID: PMC8239336, DOI: 10.1016/j.molcel.2021.03.043.
- PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesisPan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, Wajapeyee N, Müschen M. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2016553118. PMID: 33531346, PMCID: PMC7896313, DOI: 10.1073/pnas.2016553118.
- IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cellsLee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells Nature 2020, 588: 491-497. PMID: 33149299, PMCID: PMC8087162, DOI: 10.1038/s41586-020-2884-6.
- Signalling input from divergent pathways subverts B cell transformationChan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen CW, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M. Signalling input from divergent pathways subverts B cell transformation Nature 2020, 583: 845-851. PMID: 32699415, PMCID: PMC7394729, DOI: 10.1038/s41586-020-2513-4.
- Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and LeukemogenesisLee J, Xiao G, Cosgun K, Geng H, Ma N, Chan L, Kume K, Nix M, Chen Z, Chen C, Chen J, Khairnar V, Wiita A, Thomas-Tikhonenko A, Farzan M, Diamond M, Jung J, Vaidehi N, Müschen M. Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis Blood 2019, 134: 2782-2782. DOI: 10.1182/blood-2019-127615.
- Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALLXiao G, Kume K, Geng H, Han T, Klemm L, Müschen M. Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL Blood 2019, 134: 3785-3785. DOI: 10.1182/blood-2019-128719.
- Autonomous Ca2+ Oscillations Reflect Oncogenic Signaling in B-ALL CellsKume K, Chen L, Lee J, Müschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic Signaling in B-ALL Cells Blood 2019, 134: 1253-1253. DOI: 10.1182/blood-2019-130708.
- Signaling Input from Divergent Pathways Subverts Malignant B-Cell TransformationChan L, Murakami M, Caesar R, Hurtz C, Kume K, Sadras T, Shojaee S, Pölönen P, Ugale A, Lee J, Cosgun K, Geng H, Heinäniemi M, Lohi O, Wiita A, Izraeli S, Weinstock D, Müschen M. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation Blood 2019, 134: 3944-3944. DOI: 10.1182/blood-2019-130774.
- Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell TransformationCosgun K, Deb G, Yang X, Xiao G, Sadras T, Lee J, Chan L, Kume K, Yang L, Geng H, Chan J, Song J, Jumaa H, Polson A, Clevers H, Müschen M. Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation Blood 2019, 134: 748-748. DOI: 10.1182/blood-2019-127263.
- Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-SignalingLee J, Kume K, Chen Z, Xiao G, Cosgun K, Chen L, Chan L, Klemm L, Chen C, Ma N, Chan W, Forman S, Zammarchi F, Van Berkel P, Melnick A, Ngo V, Geng H, Luger S, Litzow M, McManus M, Vaidehi N, Paietta E, Meffre E, Weinstock D, Müschen M. Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling Blood 2019, 134: 393-393. DOI: 10.1182/blood-2019-131270.
- Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell MalignanciesSadras T, Martin M, Kim-Sing L, Cutler J, Lenz G, Knapp A, Ghergus D, Delmotte F, Schleiss C, Korganow A, Soulas-Sprauel P, Chen Z, Pandey A, Weinstock D, Jumaa H, Meffre E, Martin T, Müschen M. Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies Blood 2019, 134: 295-295. DOI: 10.1182/blood-2019-128999.
- Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library ScreeningQin X, Su R, Yang L, Chan A, Deng X, Qing Y, Klemm L, Müschen M, Chen C, Chen J. Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening Blood 2019, 134: 1465-1465. DOI: 10.1182/blood-2019-129849.
- Rationale for Targeting BCL6 in MLL-Rearranged B-ALLChan L, Hurtz C, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Armstrong S, Ernst P, Melnick A, Milne T, Müschen M. Rationale for Targeting BCL6 in MLL-Rearranged B-ALL Blood 2019, 134: 1239-1239. DOI: 10.1182/blood-2019-131565.
- Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug ResistanceSu R, Dong L, Li Y, Han L, Gao M, Wunderlich M, Deng X, Li H, Gao L, Li C, Robison S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Huang Y, Li W, Shen C, Sun J, Prakash K, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen M, Müschen M, Marcucci G, Ravi S, Li L, Yang C, Li Z, Mulloy J, Wei M, Horne D, Chen J. Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance Blood 2019, 134: 233-233. DOI: 10.1182/blood-2019-124535.
- Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper FunctionsPan L, Hong C, Xiao G, Geng H, Wang S, Müschen M. Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions Blood 2019, 134: 746-746. DOI: 10.1182/blood-2019-125171.
- Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemiaHurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia Genes & Development 2019, 33: 1265-1279. PMID: 31395741, PMCID: PMC6719625, DOI: 10.1101/gad.327593.119.
- Novel BAFF‐R CAR T‐cell Therapy for CD19 Antigen‐loss Relapsed B Cell TumorsKwak L, Qin H, Dong Z, Wang X, Cheng W, Smith D, Song J, Aldoss I, Muschen M, Forman S. Novel BAFF‐R CAR T‐cell Therapy for CD19 Antigen‐loss Relapsed B Cell Tumors Hematological Oncology 2019, 37: 165-166. DOI: 10.1002/hon.123_2629.
- MicroRNA-142 Is an Essential Negative Regulator of B Cell Maturation and Malignant TransformationGraham N, Wang W, Magilnick N, Lee J, Wang H, Zhang B, Marcucci G, Muschen M, Reyes E, Boldin M. MicroRNA-142 Is an Essential Negative Regulator of B Cell Maturation and Malignant Transformation The Journal Of Immunology 2019, 202: 53.22-53.22. DOI: 10.4049/jimmunol.202.supp.53.22.
- Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformationMüschen M. Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation Nature Reviews Immunology 2019, 19: 337-348. PMID: 30890785, DOI: 10.1038/s41577-019-0154-3.
- Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionallyHuang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu L, Wei M, Müschen M, Huang G, He C, Yang J, Chen J. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally Nature 2019, 567: 414-419. PMID: 30867593, PMCID: PMC6438714, DOI: 10.1038/s41586-019-1016-7.
- Autonomous Ca2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and ProliferationKume K, Chen L, Lee J, Muschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation Blood 2018, 132: 1373-1373. DOI: 10.1182/blood-2018-99-117315.
- CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell MalignanciesLee J, Kume K, Chen Z, Xiao G, Cosgun K, Chan L, Chen C, Pillai R, Chan W, Forman S, Kwak L, Zammarchi F, Van Berkel P, Weinstock D, Melnick A, Ngo V, Geng H, Luger S, Litzow M, Belot A, Uzel G, McManus M, Paietta E, Meffre E, Muschen M. CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies Blood 2018, 132: 776-776. DOI: 10.1182/blood-2018-99-117553.
- Autoimmunity Checkpoints As Therapeutic Targets in B-Cell MalignanciesChen Z, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies Blood 2018, 132: 1587-1587. DOI: 10.1182/blood-2018-99-113674.
- Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALLZhu Y, He X, Dong H, Sun J, Wang H, Zhang L, Miao Y, Jin J, Shen Y, Chen J, Muschen M, Chen C, Konopleva M, Sun W, Zhang B, Kuo Y, Carlesso N, Marcucci G, Li L. Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL Blood 2018, 132: 892-892. DOI: 10.1182/blood-2018-99-115139.
- Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor SignalingChan L, Hurtz C, Geng H, Auer F, Chen Z, Xiao G, Lee J, Cosgun K, Ye B, Muschen M. Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling Blood 2018, 132: 1336-1336. DOI: 10.1182/blood-2018-99-115514.
- Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic LeukemiaCosgun K, Hendriks R, Dickins R, Heisterkamp N, Muschen M. Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia Blood 2018, 132: 570-570. DOI: 10.1182/blood-2018-99-115522.
- Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell MalignanciesSadras T, Cutler J, Aguade-Gorgorio J, Chen Z, Cosgun K, Pandey A, Muschen M. Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies Blood 2018, 132: 3922-3922. DOI: 10.1182/blood-2018-99-116954.
- Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell MalignanciesCosgun K, Deb G, Yang X, Xiao G, Sadras T, Auer F, Lee J, Abarientos A, Mangolini M, Aghajanirefah A, Geng H, Jumaa H, Polson A, Clevers H, Muschen M. Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies Blood 2018, 132: 547-547. DOI: 10.1182/blood-2018-99-116956.
- DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic LeukemiaBraun M, Ecker V, Neumayer T, Muschen M, Ruland J, Buchner M. DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia Blood 2018, 132: 2857-2857. DOI: 10.1182/blood-2018-99-117052.
- Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell TumorsQin H, Dong Z, Wang X, Cheng W, Smith D, Song J, Aldoss I, Muschen M, Forman S, Kwak L. Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors Blood 2018, 132: 1411-1411. DOI: 10.1182/blood-2018-99-117513.
- Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic LeukemiaChan L, Shojaee S, Hurtz C, Auer F, Chen Z, Cosgun K, Geng H, Sadras T, White D, Muschen M. Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia Blood 2018, 132: 568-568. DOI: 10.1182/blood-2018-99-115536.
- SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic LeukemiaEcker V, Braun M, Neumayer T, Muschen M, Ruland J, Buchner M. SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia Blood 2018, 132: 894-894. DOI: 10.1182/blood-2018-99-117053.
- IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell TransformationLee J, Geng H, Dinson D, Xiao G, Cosgun K, Chan L, Chen Z, Farzan M, Jung J, Wiita A, Muschen M. IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation Blood 2018, 132: 552-552. DOI: 10.1182/blood-2018-99-117472.
- Autoimmunity Checkpoints in B-Cell Lineage ALLMüschen M. Autoimmunity Checkpoints in B-Cell Lineage ALL Clinical Lymphoma Myeloma & Leukemia 2018, 18: s51-s52. DOI: 10.1016/j.clml.2018.06.054.
- 1028 B-Cell Identity as A Metabolic Barrier Against Malignant TransformationMüschen M. 1028 B-Cell Identity as A Metabolic Barrier Against Malignant Transformation Experimental Hematology 2018, 64: s36-s37. DOI: 10.1016/j.exphem.2018.06.033.
- 3021 LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B CellsCosgun K, Yang X, Mangolini M, Xiao G, Abarientos A, Aghajanirefah A, Klemm L, Sadras T, Geng H, Yang L, Song Q, Zeng D, Zeng D, Jumaa H, Polson A, Clevers H, Muschen M. 3021 LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B Cells Experimental Hematology 2018, 64: s59-s60. DOI: 10.1016/j.exphem.2018.06.206.
- 3154 T-Cell Associated ZAP70 Kinase Contributes to B-Cell Receptor Signaling in Malignant LymphopoiesisSadras T, Chen Z, Klemm L, Cosgun K, Müschen M. 3154 T-Cell Associated ZAP70 Kinase Contributes to B-Cell Receptor Signaling in Malignant Lymphopoiesis Experimental Hematology 2018, 64: s99. DOI: 10.1016/j.exphem.2018.06.137.
- Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignanciesLee J, Geng H, Chen Z, Xiao G, Cosgun K, Zammarchi F, Berkel P, Melnick A, Paietta E, Muschen M. Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Cancer Research 2018, 78: 2983-2983. DOI: 10.1158/1538-7445.am2018-2983.
- Abstract 368: B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignanciesXiao G, Chen Z, Chan L, Braas D, Graeber T, Geng H, Jumaa H, Jiang X, Müschen M. Abstract 368: B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies Cancer Research 2018, 78: 368-368. DOI: 10.1158/1538-7445.am2018-368.
- Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignanciesCosgun K, Hecht A, Yang X, Mangolini M, Aghajanirefah A, Xiao G, Sadras T, Chen Z, Klemm L, Geng H, Hong C, Song Q, Zeng D, Jumaa H, Zeng D, Clevers H, Muschen M. Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies Cancer Research 2018, 78: 4515-4515. DOI: 10.1158/1538-7445.am2018-4515.
- Abstract 5469: RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibitionChan L, Shojaee S, Hurtz C, Caeser R, Xiao G, Geng H, Kornblau S, Muschen M. Abstract 5469: RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibition Cancer Research 2018, 78: 5469-5469. DOI: 10.1158/1538-7445.am2018-5469.
- Abstract 4371: Store-operated Ca2+ entry and NFATC1 -activation control oncogenic signaling in B-cell transformation and leukemogenesisKume K, Chen L, Lee J, Müschen M. Abstract 4371: Store-operated Ca2+ entry and NFATC1 -activation control oncogenic signaling in B-cell transformation and leukemogenesis Cancer Research 2018, 78: 4371-4371. DOI: 10.1158/1538-7445.am2018-4371.
- B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell MalignanciesXiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies Cell 2018, 173: 470-484.e18. PMID: 29551267, PMCID: PMC6284818, DOI: 10.1016/j.cell.2018.02.048.
- Autoimmunity checkpoints as therapeutic targets in B cell malignanciesMüschen M. Autoimmunity checkpoints as therapeutic targets in B cell malignancies Nature Reviews Cancer 2018, 18: 103-116. PMID: 29302068, DOI: 10.1038/nrc.2017.111.
- Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell MalignanciesChen Z, Hecht A, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies Blood 2017, 130: 718-718. DOI: 10.1182/blood.v130.suppl_1.718.718.
- PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying LactonasesXiao G, Hong C, Geng H, Muschen M. PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases Blood 2017, 130: 882-882. DOI: 10.1182/blood.v130.suppl_1.882.882.
- Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemiaTakao S, Chien W, Madan V, Lin D, Ding L, Sun Q, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang Y, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler H. Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia Leukemia 2017, 32: 616-625. PMID: 28904384, DOI: 10.1038/leu.2017.281.
- Abstract 1524: BCL6 modulates the TP53 and STAT pathways in gliomaChen Y, Xu L, Dutra-Clarke M, Mayakonda A, Lin D, Koh L, Chong Y, Sandanaraj E, Madan V, Yang H, Doan N, Said J, Yong W, Müschen M, Ang B, Tang C, Breunig J, Koeffler P. Abstract 1524: BCL6 modulates the TP53 and STAT pathways in glioma Cancer Research 2017, 77: 1524-1524. DOI: 10.1158/1538-7445.am2017-1524.
- Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic targetXu L, CHEN Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff S, Doan N, Said J, Yong W, Yang H, Ding L, Jiang Y, Tyner J, Ching J, Kovalik J, Müschen M, Breunig J, Lin D, Koeffler P. Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic target Cancer Research 2017, 77: 2569-2569. DOI: 10.1158/1538-7445.am2017-2569.
- Abstract 93: Transcriptional control of glucocorticoid responses in leukemiaChan L, Chen Z, Xiao G, Lee J, Cosgun K, Geng H, Cazzaniga V, Schjerven H, Dickins R, Muschen M. Abstract 93: Transcriptional control of glucocorticoid responses in leukemia Cancer Research 2017, 77: 93-93. DOI: 10.1158/1538-7445.am2017-93.
- V(D)J RecombinationMüschen M. V(D)J Recombination 2017, 4773-4777. DOI: 10.1007/978-3-662-46875-3_6171.
- Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survivalKaterndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival Nature Immunology 2017, 18: 694-704. PMID: 28369050, PMCID: PMC5540372, DOI: 10.1038/ni.3716.
- Metabolic gatekeeper function of B-lymphoid transcription factorsChan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors Nature 2017, 542: 479-483. PMID: 28192788, PMCID: PMC5621518, DOI: 10.1038/nature21076.
- Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre–B ALLSchjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre–B ALL Journal Of Experimental Medicine 2017, 214: 793-814. PMID: 28190001, PMCID: PMC5339667, DOI: 10.1084/jem.20160049.
- Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell TransformationChan L, Chen Z, Xiao G, Lee J, Geng H, Christian H, Cazzaniga V, Cazzaniga G, Dickins R, Müschen M. Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation Blood 2016, 128: 437-437. DOI: 10.1182/blood.v128.22.437.437.
- BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell TransformationChan L, Hurtz C, Xiao G, Shojaee S, Caeser R, Geng H, Melnick A, Müschen M. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation Blood 2016, 128: 438-438. DOI: 10.1182/blood.v128.22.438.438.
- Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic LeukemiaHurtz C, Chan L, Ballabio E, Willman C, Carroll W, Armstrong S, Ernst P, Melnick A, Milne T, Müschen M. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia Blood 2016, 128: 907-907. DOI: 10.1182/blood.v128.22.907.907.
- IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell MalignanciesLee J, Geng H, Cosgun K, Chan L, Chen Z, Park E, Klemm L, Bailey C, Müschen M. IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies Blood 2016, 128: 2738-2738. DOI: 10.1182/blood.v128.22.2738.2738.
- mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALLGotesman M, Vo T, Mallya S, Zhang Q, Shi C, Müschen M, Weinstock D, Mullighan C, Tasian S, Konopleva M, Fruman D. mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL Blood 2016, 128: 2763-2763. DOI: 10.1182/blood.v128.22.2763.2763.
- Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic LeukemiaChan L, Lee J, Cosgun K, Geng H, Xiao G, Chen Z, Ernst T, Hochhaus A, Müschen M. Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2016, 128: 2771-2771. DOI: 10.1182/blood.v128.22.2771.2771.
- Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose MetabolismChen Z, Geng H, Klemm L, Chan L, Daniel B, Alexander W, Willman C, Müschen M. Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism Blood 2016, 128: 4069-4069. DOI: 10.1182/blood.v128.22.4069.4069.
- Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted TreatmentsTeppo S, Mehtonen J, Eldfors S, Heckman C, Müschen M, Heinäniemi M, Lohi O. Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments Blood 2016, 128: 4077-4077. DOI: 10.1182/blood.v128.22.4077.4077.
- CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell MalignanciesLee J, Geng H, Chen Z, Klemm L, Cosgun K, Xiao G, Masouleh B, Hurtz C, Parekh S, Kornblau S, Melnick A, Abbas A, Paietta E, Müschen M. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies Blood 2016, 128: 4088-4088. DOI: 10.1182/blood.v128.22.4088.4088.
- PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic LeukemiaXiao G, Chen Z, Daniel B, Chan L, Geng H, Jiang X, Müschen M. PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia Blood 2016, 128: 1056-1056. DOI: 10.1182/blood.v128.22.1056.1056.
- Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activationMcCracken A, McMonigle R, Tessier J, Fransson R, Perryman M, Chen B, Keebaugh A, Selwan E, Barr S, Kim S, Roy S, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider A, Clare S, Müschen M, Huwiler A, Kleinman M, Hanessian S, Edinger A. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation Leukemia 2016, 31: 669-677. PMID: 27573555, PMCID: PMC5332311, DOI: 10.1038/leu.2016.244.
- Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemiaKöhrer S, Seyfried F, Debatin K, Müschen M, Meyer L, Davis R, Burger J. Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemia Klinische Pädiatrie 2016, 228 DOI: 10.1055/s-0036-1582492.
- Analysis of Ikaros tumor suppressor function in BCR-ABL1+ pre-B ALL reveals conserved target genes and biological pathwaysSchjerven H, Ayongaba E, McLaughlin J, Cheng D, Eggesbø L, Lindeman I, Park E, Witte O, Smale S, Frietze S, Muschen M. Analysis of Ikaros tumor suppressor function in BCR-ABL1+ pre-B ALL reveals conserved target genes and biological pathways The Journal Of Immunology 2016, 196: 122.6-122.6. DOI: 10.4049/jimmunol.196.supp.122.6.
- Role of the transcription factor Ikaros in development of autoimmune diseaseSchjerven H, Frietze S, Hai S, Hermiston M, Kogan S, Muschen M. Role of the transcription factor Ikaros in development of autoimmune disease The Journal Of Immunology 2016, 196: 47.14-47.14. DOI: 10.4049/jimmunol.196.supp.47.14.
- PTEN opposes negative selection and enables oncogenic transformation of pre-B cellsShojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells Nature Medicine 2016, 22: 379-387. PMID: 26974310, PMCID: PMC5178869, DOI: 10.1038/nm.4062.
- Correction: Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemiaChen Z, Shojaee S, Buchner M, Geng H, Lee J, Klemm L, Titz B, Graeber T, Park E, Tan Y, Satterthwaite A, Paietta E, Hunger S, Willman C, Melnick A, Loh M, Jung J, Coligan J, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell C, Müschen M. Correction: Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia Nature 2016, 534: 138-138. PMID: 26958840, DOI: 10.1038/nature16997.
- Abstract PR11: Targeted engagement of B cell autoimmunity checkpoints to overcome drug resistance in pediatric Ph-like ALLChen Z, Geng H, Lowell C, Hunger S, Müschen M. Abstract PR11: Targeted engagement of B cell autoimmunity checkpoints to overcome drug resistance in pediatric Ph-like ALL Cancer Research 2016, 76: pr11-pr11. DOI: 10.1158/1538-7445.pedca15-pr11.
- BCOR regulates myeloid cell proliferation and differentiationCao Q, Gearhart M, Gery S, Shojaee S, Yang H, Sun H, Lin D, Bai J, Mead M, Zhao Z, Chen Q, Chien W, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell V, Koeffler H. BCOR regulates myeloid cell proliferation and differentiation Leukemia 2016, 30: 1155-1165. PMID: 26847029, PMCID: PMC5131645, DOI: 10.1038/leu.2016.2.
- Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibitionKöhrer S, Havranek O, Seyfried F, Hurtz C, Coffey G, Kim E, ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas D, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin K, Müschen M, Meyer L, Davis R, Burger J. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition Leukemia 2016, 30: 1246-1254. PMID: 26847027, PMCID: PMC5459356, DOI: 10.1038/leu.2016.9.
- Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemiaSong C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne K, Dovat S. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia Leukemia 2015, 30: 1436-1440. PMID: 26639180, PMCID: PMC4889471, DOI: 10.1038/leu.2015.331.
- Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic LeukemiaChen Z, Geng H, Lowell C, Weiss A, Hunger S, Melnick A, Muschen M. Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia Blood 2015, 126: 3716-3716. DOI: 10.1182/blood.v126.23.3716.3716.
- Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair InhibitorsSullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Blood 2015, 126: 50-50. DOI: 10.1182/blood.v126.23.50.50.
- Circadian Clock Protein CRY Controls B-Cell Intrinsic ToleranceCao Q, Zhao X, Gery S, Chen Z, Deng R, Sun H, Lin D, Zhao Z, Said J, Li Q, Muschen M, Evans R, Koeffler H. Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance Blood 2015, 126: 1029-1029. DOI: 10.1182/blood.v126.23.1029.1029.
- B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic SignalingChan L, Chen Z, Braas D, Geng H, Hurtz C, Shojaee S, Cazzaniga V, Ng C, Ernst T, Hochhaus A, Kornblau S, Cazzaniga G, Liu G, Milne T, Koeffler H, Armstrong S, Dickins R, Yamamoto K, Graeber T, Muschen M. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling Blood 2015, 126: 1255-1255. DOI: 10.1182/blood.v126.23.1255.1255.
- IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL CellsLee J, Geng H, Chen Z, PARK E, Klemm L, Bailey C, Muschen M. IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells Blood 2015, 126: 1325-1325. DOI: 10.1182/blood.v126.23.1325.1325.
- Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center FormationDeng R, Hurtz C, Yue C, Xiao G, Yu H, Muschen M, Forman S, Martin P, Zeng D. Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation Blood 2015, 126: 1875-1875. DOI: 10.1182/blood.v126.23.1875.1875.
- CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic LeukemiaLee J, Chen Z, Geng H, Xiao G, PARK E, Parekh S, Kornblau S, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia Blood 2015, 126: 1434-1434. DOI: 10.1182/blood.v126.23.1434.1434.
- Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic LeukemiaKlemm L, Swaminathan S, Papaemmanuil E, Ford A, Greaves M, Casellas R, Schatz D, Lieber M, Muschen M. Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia Blood 2015, 126: 166-166. DOI: 10.1182/blood.v126.23.166.166.
- Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10Gang E, Hsieh Y, Kim H, Duchartre Y, Stephanie S, Muschen M, Wayner E, Heisterkamp N, Bonig H, Kim Y. Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10 Blood 2015, 126: 2525-2525. DOI: 10.1182/blood.v126.23.2525.2525.
- Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic LeukemiaShi C, Han L, Zhang Q, Roberts K, Park E, Tabe Y, Jacamo R, Mu H, Wu S, Zhou J, Ma H, Zeng Z, Jain N, Jabbour E, Muschen M, Tasian S, Mullighan C, Weinstock D, Fruman D, Konopleva M. Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia Blood 2015, 126: 2529-2529. DOI: 10.1182/blood.v126.23.2529.2529.
- Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic LeukemiaLi Q, Hurtz C, Shojaee S, Chen Z, Geng H, Xiao G, Loh M, Ye B, Melnick A, Muschen M. Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia Blood 2015, 126: 556-556. DOI: 10.1182/blood.v126.23.556.556.
- PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic LeukemiaGang X, Geng H, Chan L, Chen Z, Jiang X, Muschen M. PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2015, 126: 902-902. DOI: 10.1182/blood.v126.23.902.902.
- Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic LeukemiaGeng H, Chen Z, Anderson S, Fraser E, Lu M, Lingjing C, Collins C, Markus M, Rubenstein J. Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia Blood 2015, 126: 3900-3900. DOI: 10.1182/blood.v126.23.3900.3900.
- Abstract 2075: Signaling thresholds and negative B cell selection in acute lymphoblastic leukemiaChen Z, Shojaee S, Buchner M, Geng H, Lee J, Klemm L, Park E, Tan Y, Satterthwaite A, Paietta E, Hunger S, Loh M, Jung J, Coligan J, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell C, Müschen M. Abstract 2075: Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia 2015, 2075-2075. DOI: 10.1158/1538-7445.am2015-2075.
- Abstract 4944: Identification of B-cell lymphoma 6 as a novel therapeutic target in glioblastomaChen Y, Xu L, Hazawa M, Thippeswamy A, Yang H, Müschen M, Lin D, Koeffler P. Abstract 4944: Identification of B-cell lymphoma 6 as a novel therapeutic target in glioblastoma 2015, 4944-4944. DOI: 10.1158/1538-7445.am2015-4944.
- Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic LeukemiaShojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Cancer Cell 2015, 28: 114-128. PMID: 26073130, PMCID: PMC4565502, DOI: 10.1016/j.ccell.2015.05.008.
- Mechanisms of clonal evolution in childhood acute lymphoblastic leukemiaSwaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia Nature Immunology 2015, 16: 766-774. PMID: 25985233, PMCID: PMC4475638, DOI: 10.1038/ni.3160.
- Ikaros tumor suppressor function in pre-B ALL: potential role of Ikaros target gene Ctnnd1 (IRM10P.621)Schjerven H, Eggesbo L, Lindeman I, Muschen M. Ikaros tumor suppressor function in pre-B ALL: potential role of Ikaros target gene Ctnnd1 (IRM10P.621) The Journal Of Immunology 2015, 194: 131.19-131.19. DOI: 10.4049/jimmunol.194.supp.131.19.
- STAT5 antagonism of B cell superenhancer networks initiates progenitor B cell leukemia and predicts patient survival (HEM1P.222)Farrar M, Katerndahl C, Heltemes Harris L, Willette M, Henzler C, Yang R, Silverstein K, Frietze S, Schjerven H, Ramsey L, Hubbard G, Muschen M, Kornblau S. STAT5 antagonism of B cell superenhancer networks initiates progenitor B cell leukemia and predicts patient survival (HEM1P.222) The Journal Of Immunology 2015, 194: 50.5-50.5. DOI: 10.4049/jimmunol.194.supp.50.5.
- Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemiaChen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia Nature 2015, 521: 357-361. PMID: 25799995, PMCID: PMC4441554, DOI: 10.1038/nature14231.
- Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemiaBuchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia Nature Communications 2015, 6: 6471. PMID: 25753524, PMCID: PMC4366523, DOI: 10.1038/ncomms7471.
- Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic LeukemiaGeng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Cancer Cell 2015, 27: 409-425. PMID: 25759025, PMCID: PMC4618684, DOI: 10.1016/j.ccell.2015.02.003.
- IFITM3 (CD225) Regulates CD19 Surface Expression and CD19-Mediated Activation of PI3K Signaling in Pre-B Acute Lymphoblastic Leukemia CellsLee J, Geng H, Chen Z, Park E, Park A, Klemm L, Bailey C, Muschen M. IFITM3 (CD225) Regulates CD19 Surface Expression and CD19-Mediated Activation of PI3K Signaling in Pre-B Acute Lymphoblastic Leukemia Cells Blood 2014, 124: 1070-1070. DOI: 10.1182/blood.v124.21.1070.1070.
- Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast CrisisXiao G, Geng H, Chan L, Chen Z, Muschen M. Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast Crisis Blood 2014, 124: 3128-3128. DOI: 10.1182/blood.v124.21.3128.3128.
- BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic LeukemiaHurtz C, Geng H, Xiao G, Loh M, Ye B, Melnick A, Muschen M. BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia Blood 2014, 124: 3570-3570. DOI: 10.1182/blood.v124.21.3570.3570.
- Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor CellsNieborowska-Skorska M, Sullivan K, Podszywalow-Bartnicka P, Hoser G, Bolton-Gillespie E, Cramer-Morales K, Slupianek A, Zhou C, Cerny-Reiterer S, Stoklosa T, Sykes S, Valent P, Civin C, Muschen M, Minden M, Eppert K, Skorski T. Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells Blood 2014, 124: 480-480. DOI: 10.1182/blood.v124.21.480.480.
- BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven LeukemiaPark E, Swaminathan S, Sadiyah M, Igarashi K, Melnick A, Muschen M. BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia Blood 2014, 124: 513-513. DOI: 10.1182/blood.v124.21.513.513.
- Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic LeukemiaChan L, Braas D, Hurtz C, Shojaee S, Kharabi Masouleh B, Geng H, Ernst T, Hochhaus A, Graeber T, Muschen M. Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2014, 124: 783-783. DOI: 10.1182/blood.v124.21.783.783.
- Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic LeukemiaSeyedmehdi S, Chen Z, Buchner M, Hurtz C, Geng H, Schjerven H, Chan L, Koeffler P, Willman C, Hunger S, Dovat S, Paietta E, Hofmann W, Melnick A, Alexander W, Kornblau S, Muschen M. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2014, 124: 787-787. DOI: 10.1182/blood.v124.21.787.787.
- IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic LeukemiaGeng H, Lee J, Chen Z, Kharabi Masouleh B, Hurtz C, Park E, Xiao G, Parekh S, Kornblau S, Melnick A, Paietta E, Muschen M. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia Blood 2014, 124: 788-788. DOI: 10.1182/blood.v124.21.788.788.
- FOXM1 Mediates Drug-Resistance and Represents a Therapeutic Target in Pre-B Acute Lymphoblastic LeukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. FOXM1 Mediates Drug-Resistance and Represents a Therapeutic Target in Pre-B Acute Lymphoblastic Leukemia Blood 2014, 124: 790-790. DOI: 10.1182/blood.v124.21.790.790.
- Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic LeukemiaChen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell C, Paietta E, Willman C, Carroll W, Melnick A, Jung J, Jumaa H, Coligan J, Bolland S, Mak T, Muschen M. Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood 2014, 124: 792-792. DOI: 10.1182/blood.v124.21.792.792.
- Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic LeukemiaSwaminathan S, Klemm L, Park E, Ford A, Kweon S, Trageser D, Hasselfeld B, Henke N, Geng H, Schwarz K, Casellas R, Schatz D, Lieber M, Papaemmanuil E, Greaves M, Muschen M. Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic Leukemia Blood 2014, 124: 861-861. DOI: 10.1182/blood.v124.21.861.861.
- The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic LeukemiaLee J, Buchner M, Geng H, Swaminathan S, Park E, Park A, Lin-Chao S, So C, Muschen M. The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic Leukemia Blood 2014, 124: 3777-3777. DOI: 10.1182/blood.v124.21.3777.3777.
- PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B CellsShojaee S, Cazzaniga V, Schjerven H, Buchner M, Hurtz C, Geng H, Hochhaus A, Cazzaniga G, Melnick A, Kornblau S, Graeber T, Muschen M. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells Blood 2014, 124: 262-262. DOI: 10.1182/blood.v124.21.262.262.
- Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic LeukemiaGeng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan L, Yu J, Tyner J, Chang B, Kornblau S, Bijl J, Ye B, Paietta E, Melnick A, Roeder R, Hunger S, Loh M, Milne T, Muschen M. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood 2014, 124: 284-284. DOI: 10.1182/blood.v124.21.284.284.
- Abstract 2447: Lineage-specific metabolic reprogramming in BCR-ABL1-driven leukemiaChan L, Shojaee S, Hurtz C, Geng H, Ng C, Kharabi B, Müschen M. Abstract 2447: Lineage-specific metabolic reprogramming in BCR-ABL1-driven leukemia 2014, 2447-2447. DOI: 10.1158/1538-7445.am2014-2447.
- Abstract 484: Identification of FOXM1 as therapeutic target in Philadelphia chromosome-positive acute lymphoblastic leukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Müschen M. Abstract 484: Identification of FOXM1 as therapeutic target in Philadelphia chromosome-positive acute lymphoblastic leukemia 2014, 484-484. DOI: 10.1158/1538-7445.am2014-484.
- Abstract 510: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemiaSun H, Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Masouleh K, Müschen M, Koeffler H. Abstract 510: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia 2014, 510-510. DOI: 10.1158/1538-7445.am2014-510.
- Biology and targeting options for kinase signaling in acute lymphoblastic leukemiaShojaee S, Muschen M. Biology and targeting options for kinase signaling in acute lymphoblastic leukemia AACR Education Book 2014, 2014: 91. DOI: 10.1158/aacr.edb-14-1332.
- BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid LeukemiaPan R, Debose L, Benito J, Golfman L, Zweidler-McKay P, Han L, Harutyunyan K, Mu H, Ruvolo V, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian H, Ruvolo P, Andreeff M, Konopleva M. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia Blood 2013, 122: 1456-1456. DOI: 10.1182/blood.v122.21.1456.1456.
- Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic LeukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia Blood 2013, 122: 1250-1250. DOI: 10.1182/blood.v122.21.1250.1250.
- Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic LeukemiaKim E, Koehrer S, Rosin N, Wang Z, Thomas D, Ravandi F, Kornblau S, Kantarjian H, O'Brien S, Estrov Z, Buggy J, Muschen M, Davis R, Burger J. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia Blood 2013, 122: 1399-1399. DOI: 10.1182/blood.v122.21.1399.1399.
- Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive LeukemiasDasgupta Y, Koptyra M, Nieborowska-Skorska M, Gillespie E, Stoklosa T, Hoser G, Wasik M, Muschen M, Richardson C, Skorski T. Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias Blood 2013, 122: 1466-1466. DOI: 10.1182/blood.v122.21.1466.1466.
- Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199Konopleva M, Benito J, Harutyunyan K, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy J, Bendall L, Zweidler-McKay P, Coombes K, Qiu Y, Zhang N, Leverson J, Thomas D, O'Brien S, Kantarjian H, Kornblau S, Andreeff M. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 Blood 2013, 122: 3919-3919. DOI: 10.1182/blood.v122.21.3919.3919.
- Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALLHurtz C, Geng H, Ballabio E, Xiao G, Ng C, Masouleh B, Willman C, Armstrong S, Milne T, Melnick A, Muschen M. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL Blood 2013, 122: 72-72. DOI: 10.1182/blood.v122.21.72.72.
- Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor CellsNieborowska-Skorska M, Slupianek A, Hoser G, Bolton-Gillespie E, Tulin A, Cerny-Reiterer S, Valent P, Muschen M, Sykes S, Skorski T. Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells Blood 2013, 122: 810-810. DOI: 10.1182/blood.v122.21.810.810.
- The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALLMasouleh B, Geng H, Hurtz C, Huang C, Chan L, Swaminathan S, Sun H, Koeffler H, Melnick A, Paietta E, Glimcher L, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL Blood 2013, 122: 836-836. DOI: 10.1182/blood.v122.21.836.836.
- Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALLLee J, Geng H, Chen Z, Park E, Klemm L, Bailey C, Muschen M. Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL Blood 2013, 122: 2505-2505. DOI: 10.1182/blood.v122.21.2505.2505.
- Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B CellsLee J, Buchner M, Geng H, Swaminathan S, Park E, Klemm L, Lin-Chao S, So C, Muschen M. Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells Blood 2013, 122: 2506-2506. DOI: 10.1182/blood.v122.21.2506.2506.
- Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage LeukemiaChen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell C, Paietta E, Willman C, Carroll W, Melnick A, Jung J, Jumaa H, Coligan J, Bolland S, Mak T, Muschen M. Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia Blood 2013, 122: 229-229. DOI: 10.1182/blood.v122.21.229.229.
- Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic LeukemiaGeng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan L, Masouleh B, Sykes D, Melnick A, Roeder R, Milne T, Muschen M. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood 2013, 122: 349-349. DOI: 10.1182/blood.v122.21.349.349.
- Abstract A55: Induced hyperactivation of Ras-MAPK in chronic myeloid leukemia: role of negative feedback signalingSilveira V, Shojaee S, Müschen M. Abstract A55: Induced hyperactivation of Ras-MAPK in chronic myeloid leukemia: role of negative feedback signaling Cancer Research 2013, 73: a55-a55. DOI: 10.1158/1538-7445.fbcr13-a55.
- BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpointSwaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint Nature Medicine 2013, 19: 1014-1022. PMID: 23852341, PMCID: PMC3954721, DOI: 10.1038/nm.3247.
- Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL.Shojaee S, Buchner M, Gery S, Geng H, Chan L, Melnick A, Koeffler P, Müschen M. Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL. Cancer Research 2013, 73: 2334-2334. DOI: 10.1158/1538-7445.am2013-2334.
- Abstract 2030: Inhibition of IRE1α-XBP1 pathway is a promising therapeutic application in acute myeloid leukemia.Sun H, Masouleh B, Gery S, Cao Q, Yin T, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Yang J, Agelopoulos K, Markus M, Koeffler H. Abstract 2030: Inhibition of IRE1α-XBP1 pathway is a promising therapeutic application in acute myeloid leukemia. Cancer Research 2013, 73: 2030-2030. DOI: 10.1158/1538-7445.am2013-2030.
- Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic LeukemiaSwaminathan S, Klemm L, Ford A, Schwarz K, Casellas R, Hennighausen L, Geng H, Schatz D, Lieber M, Greaves M, Muschen M. Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia Blood 2012, 120: 519-519. DOI: 10.1182/blood.v120.21.519.519.
- Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALLGeng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner J, Chang B, Titz B, Buchner M, Hurtz C, Graeber T, Druker B, Paietta E, Melnick A, Willman C, Carroll W, Muschen M. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood 2012, 120: 528-528. DOI: 10.1182/blood.v120.21.528.528.
- Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALLHurtz C, Ramezani-Rad P, Geng H, Kharabi B, Carroll W, Willman C, Armstrong S, Melnick A, Muschen M. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL Blood 2012, 120: 776-776. DOI: 10.1182/blood.v120.21.776.776.
- SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic LeukemiaRamezani-Rad P, Geng H, Chan L, Hurtz C, Jumaa H, Melnick A, Paietta E, Carroll W, Willman C, Lefebvre V, Muschen M. SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia Blood 2012, 120: 863-863. DOI: 10.1182/blood.v120.21.863.863.
- Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALLMasouleh B, Hurtz C, Geng H, Ramezani-Rad P, Glimcher L, Muschen M. Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL Blood 2012, 120: 872-872. DOI: 10.1182/blood.v120.21.872.872.
- Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALLBuchner M, Klemm L, Zhengshan C, Geng H, Muschen M. Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL Blood 2012, 120: 874-874. DOI: 10.1182/blood.v120.21.874.874.
- BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor SurveillanceSwaminathan S, Kang H, Harvey R, Huang C, Buchner M, Chen Z, Geng H, Hall A, Igarashi K, Carroll W, Willman C, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance Blood 2012, 120: 1300-1300. DOI: 10.1182/blood.v120.21.1300.1300.
- BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid LeukemiaShojaee S, Geng H, Gearhart M, Bardwell V, Muschen M. BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia Blood 2012, 120: 1301-1301. DOI: 10.1182/blood.v120.21.1301.1301.
- Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine KinasesShojaee S, Buchner M, Swaminathan S, Geng H, Chan L, Bothe M, Chen Z, Melnick A, Molkentin J, Martin G, Koeffler H, Muschen M. Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases Blood 2012, 120: 1352-1352. DOI: 10.1182/blood.v120.21.1352.1352.
- ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALLChen Z, Geng H, Buchner M, Klemm L, Hemati K, Shojaee S, Tak M, Coligan J, Carroll W, Willman C, Muschen M. ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL Blood 2012, 120: 291-291. DOI: 10.1182/blood.v120.21.291.291.
- Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.Chen Z, Geng H, Klemm L, Buchner M, Hemati K, Shojaee S, Alexander W, Carroll W, Willman C, Muschen M. Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood 2012, 120: 2563-2563. DOI: 10.1182/blood.v120.21.2563.2563.
- Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.Gang E, Hsieh Y, Geng H, Pham J, Muschen M, de Arcangelis A, Willman C, Carroll W, Georges-Labouesse E, Bonig H, Kim Y. Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. Blood 2012, 120: 2565-2565. DOI: 10.1182/blood.v120.21.2565.2565.
- Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast CrisisChan L, Geng H, Muschen M. Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis Blood 2012, 120: 34-34. DOI: 10.1182/blood.v120.21.34.34.
- BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox GenesCao Q, Gery S, Shojaee S, Gearhart M, Bardwell V, Muschen M, Koeffler H. BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes Blood 2012, 120: 3445-3445. DOI: 10.1182/blood.v120.21.3445.3445.
- YM155 sensitivity in pediatric acute lymphoblastic leukemia.Chang B, Jemal A, Tyner J, Thayer M, Muschen M, Druker B. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal Of Clinical Oncology 2012, 30: 9555-9555. DOI: 10.1200/jco.2012.30.15_suppl.9555.
- Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignanciesShojaee S, Buchner M, Swaminathan S, Chan L, Bothe M, Geng H, Melnick A, Molkentin J, Martin G, Koeffler P, Muschen M. Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies Cancer Research 2012, 72: 2944-2944. DOI: 10.1158/1538-7445.am2012-2944.
- V(D)J RecombinationMüschen M. V(D)J Recombination 2012, 1-5. DOI: 10.1007/978-3-642-27841-9_6171-2.
- Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic LeukemiaBicocca V, Chang B, Muschen M, Druker B, Tyner J. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia Blood 2011, 118: 2466-2466. DOI: 10.1182/blood.v118.21.2466.2466.
- Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic LeukemiaJemal A, Tyner J, Thayer M, Muschen M, Druker B, Chang B. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia Blood 2011, 118: 2490-2490. DOI: 10.1182/blood.v118.21.2490.2490.
- Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven LeukemiasShojaee S, Buchner M, Geng H, Silvia B, Koeffler P, Muschen M. Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias Blood 2011, 118: 1382-1382. DOI: 10.1182/blood.v118.21.1382.1382.
- Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYCNahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Jumaa H, Ye B, Melnick A, Muschen M. Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC Blood 2011, 118: 1406-1406. DOI: 10.1182/blood.v118.21.1406.1406.
- DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell SurvivalShojaee S, Buchner M, Geng H, Melnick A, Gery S, Molkentin J, Koeffler P, Muschen M. DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival Blood 2011, 118: 1479-1479. DOI: 10.1182/blood.v118.21.1479.1479.
- Mechanisms of Ikaros-Mediated Tumor SuppressionNahar R, Ramezani-Rad P, Dovat S, Buchner M, Graeber T, Muschen M. Mechanisms of Ikaros-Mediated Tumor Suppression Blood 2011, 118: 408-408. DOI: 10.1182/blood.v118.21.408.408.
- BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid LeukemiaHurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller M, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker B, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood 2011, 118: 446-446. DOI: 10.1182/blood.v118.21.446.446.
- BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic LeukemiaSwaminathan S, Huang C, Titz B, Buchner M, Geng H, Graeber T, Willman C, Igarashi K, Melnick A, Muschen M. BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia Blood 2011, 118: 562-562. DOI: 10.1182/blood.v118.21.562.562.
- Infectious Origins of Childhood LeukemiaKlemm L, Swaminathan S, Ford A, Schwarz K, Schatz D, Lieber M, Greaves M, Muschen M. Infectious Origins of Childhood Leukemia Blood 2011, 118: 751-751. DOI: 10.1182/blood.v118.21.751.751.
- BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemiaHurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia Journal Of Experimental Medicine 2011, 208: 2163-2174. PMID: 21911423, PMCID: PMC3201200, DOI: 10.1084/jem.20110304.
- BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibitionDuy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition Nature 2011, 473: 384-388. PMID: 21593872, PMCID: PMC3597744, DOI: 10.1038/nature09883.
- Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells in vitro and in vivoNguyen T, Attkisson E, Dai Y, Kramer L, Muschen M, Grant S. Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells in vitro and in vivo Cancer Research 2011, 71: 2572-2572. DOI: 10.1158/1538-7445.am2011-2572.
- Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibitionDuy C, Hurtz C, Koeffler P, Melnick A, Müschen M. Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition Cancer Research 2011, 71: lb-235-lb-235. DOI: 10.1158/1538-7445.am2011-lb-235.
- Abstract LB-25: Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signalingRubbi L, Titz B, Brown L, Glavan E, Komisopoulou E, Chen S, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber T. Abstract LB-25: Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling Cancer Research 2011, 71: lb-25-lb-25. DOI: 10.1158/1538-7445.am2011-lb-25.
- V(D)J RecombinationMüschen M. V(D)J Recombination 2011, 3875-3879. DOI: 10.1007/978-3-642-16483-5_6171.
- WNT/β-Catenin Signaling in LeukemiaMüschen M. WNT/β-Catenin Signaling in Leukemia 2010, 129-142. DOI: 10.1007/978-1-4419-8023-6_6.
- ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1Thai M, Ting P, McLaughlin J, Cheng D, Müschen M, Witte O, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1 Leukemia 2010, 25: 290-300. PMID: 21102429, PMCID: PMC3049868, DOI: 10.1038/leu.2010.268.
- IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell ReceptorNahar R, Ramezani-Rad P, Duy C, Dovat S, Ye B, Melnick A, Muschen M. IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor Blood 2010, 116: 146-146. DOI: 10.1182/blood.v116.21.146.146.
- Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic LeukemiaDuy C, Nowak D, Klemm L, Nahar R, Ng C, Elliott E, Hofmann W, Heisterkamp N, Lowell C, Koeffler P, Muschen M. Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia Blood 2010, 116: 147-147. DOI: 10.1182/blood.v116.21.147.147.
- IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood LeukemiaSwaminathan S, Klemm L, Kweon S, Ford A, Schwarz K, Casellas R, Hennighausen L, Schatz D, Lieber M, Greaves M, Muschen M. IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia Blood 2010, 116: 26-26. DOI: 10.1182/blood.v116.21.26.26.
- BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid LeukemiaHurtz C, Duy C, Cerchietti L, Chatzi K, Park E, Klemm L, Kim Y, Kahn M, Braig M, Muller M, Hochhaus A, Ye B, Melnick A, Muschen M. BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia Blood 2010, 116: 202-202. DOI: 10.1182/blood.v116.21.202.202.
- VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL)Miles R, Downie J, Jahromi M, Joshi D, Rodic V, Muschen M, Yang J, Evans W, Meeker N, Trede N, Frazer J, Barnette P, Schiffman J. VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL) Blood 2010, 116: 273-273. DOI: 10.1182/blood.v116.21.273.273.
- Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic LeukemiaNahar R, Trageser D, Klemm L, Duy C, Hofmann W, Park E, Kim Y, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia Blood 2010, 116: 274-274. DOI: 10.1182/blood.v116.21.274.274.
- Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor GenesIwanski G, Thoennissen N, Nakitandwe J, Lin P, Kawamata N, Nahar R, Ramezani-Rad P, Chen S, Shurtleff S, Nowak D, Ruckert C, Dugas M, Bokemeyer C, Fazio G, Biondi A, Cazzaniga G, Downing J, Müschen M, Koeffler H. Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor Genes Blood 2010, 116: 3231-3231. DOI: 10.1182/blood.v116.21.3231.3231.
- Targeting Survivin In Recalcitrant Acute Lymphoblastic LeukemiaPark E, Jiang E, Hsieh Y, Klemm L, Duy C, Conway E, Pelus L, Crispino J, Loh M, Kang E, Koo H, Yang A, Heisterkamp N, Kahn M, Muschen M, Kim Y. Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia Blood 2010, 116: 3263-3263. DOI: 10.1182/blood.v116.21.3263.3263.
- Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-CateninJiang E, Park E, Nguyen C, Yoon J, Hsieh Y, Loh M, Muschen M, Kahn M, Kim Y. Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin Blood 2010, 116: 3264-3264. DOI: 10.1182/blood.v116.21.3264.3264.
- SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic TargetNg C, Nahar R, Elliott E, Lowell C, Muschen M. SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target Blood 2010, 116: 4199-4199. DOI: 10.1182/blood.v116.21.4199.4199.
- The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid LeukemiaShojaee S, Garcia C, Wu H, Muschen M. The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia Blood 2010, 116: 513-513. DOI: 10.1182/blood.v116.21.513.513.
- ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic LeukemiaBicocca V, Chang B, Muschen M, Druker B, Tyner J. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia Blood 2010, 116: 539-539. DOI: 10.1182/blood.v116.21.539.539.
- Adjuvant CD49d Blockade Eradicates Chemoresistant ALLHsieh Y, Park E, Jiang E, Dauber K, Chudziak D, Schaefer P, Klemm L, Scharman C, Kang E, Koo H, Loh M, Hofmann W, Heisterkamp N, Muschen M, Shimada H, Bonig H, Kim Y. Adjuvant CD49d Blockade Eradicates Chemoresistant ALL Blood 2010, 116: 869-869. DOI: 10.1182/blood.v116.21.869.869.
- Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemiaFei F, Stoddart S, Müschen M, Kim Y, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia Leukemia 2010, 24: 813-820. PMID: 20111071, PMCID: PMC3038787, DOI: 10.1038/leu.2009.302.
- Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1-Driven B Cell Lineage Acute Lymphoblastic Leukemia.Gruber T, Chang M, Sposto R, Müschen M. Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1-Driven B Cell Lineage Acute Lymphoblastic Leukemia. Blood 2009, 114: 181-181. DOI: 10.1182/blood.v114.22.181.181.
- BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.Duy C, Cerchietti L, Yu J, Ci W, Swaminathan S, Nahar R, Kweon S, Klemm L, Ye B, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood 2009, 114: 765-765. DOI: 10.1182/blood.v114.22.765.765.
- BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.Duy C, Yu J, Swaminathan S, Nahar R, Kweon S, Polo J, Valls E, Klemm L, Cerchietti L, von Levetzow G, Herzog S, Jumaa H, de Alborán I, Melnick A, Ye B, Müschen M. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood 2009, 114: 91-91. DOI: 10.1182/blood.v114.22.91.91.
- IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.Iacobucci I, Messina M, Iraci N, Lonetti A, Chiaretti S, Ferrari A, Papayannidis C, Messa F, Vitale A, Paoloni F, Cilloni D, Storlazzi C, Ottaviani E, Paolini S, Durante S, Soverini S, Guarini R, Vignetti M, Pane F, Saglio G, Foà R, Muschen M, Pfifer H, Ottmann O, Perini G, Baccarani M, Martinelli G. IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. Blood 2009, 114: 912-912. DOI: 10.1182/blood.v114.22.912.912.
- Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia.Park E, Jiang E, von Levetzow G, Duy C, Klemm L, Hsieh Y, Kadavallore A, Ma H, Zhao Y, Nguyen C, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 10-10. DOI: 10.1182/blood.v114.22.10.10.
- Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression.Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Muschen M, Sumerle L, Papayannidis C, Soverini S, Ottaviani E, Paolini S, Ferrari A, Messa F, Cilloni D, Vitale A, Pane F, Saglio G, Foà R, Baccarani M, Delledonne M, Martinelli G. Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression. Blood 2009, 114: 3074-3074. DOI: 10.1182/blood.v114.22.3074.3074.
- PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.Iacobucci I, Papayannidis C, Paoloni F, Lonetti A, Muschen M, Vignetti M, Cilloni D, Soverini S, Messa F, Paolini S, Chiaretti S, Guadagnuolo V, Fazi P, Vitale A, Meloni G, Gobbi M, Malagola M, Saglio G, Pane F, Baccarani M, Foà R, Martinelli G. PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party. Blood 2009, 114: 12-12. DOI: 10.1182/blood.v114.22.12.12.
- The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines.Nowak D, Kawamata N, Niebuhr B, Nowak V, Mossner M, Nahar R, Thoennissen N, Iwanski G, Stocking C, Dugas M, Hofmann W, Müschen M, Koeffler P. The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. Blood 2009, 114: 1284-1284. DOI: 10.1182/blood.v114.22.1284.1284.
- Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species.Chang M, Wey S, Lee A, Müschen M. Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species. Blood 2009, 114: 1976-1976. DOI: 10.1182/blood.v114.22.1976.1976.
- BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye B, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood 2009, 114: 2167-2167. DOI: 10.1182/blood.v114.22.2167.2167.
- Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.Jiang E, Park E, Scharman C, Hsieh Y, Kadavallore A, Nguyen C, Zhao Y, McMillan M, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 3072-3072. DOI: 10.1182/blood.v114.22.3072.3072.
- The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia.Klemm L, Duy C, Iacobucci I, von Levetzow G, Feldhahn N, Kim Y, Hofmann W, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber M, Casellas R, Müschen M. The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia. Blood 2009, 114: 3274-3274. DOI: 10.1182/blood.v114.22.3274.3274.
- Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia.Duy C, Sprangers M, Klemm L, Nahar R, Nowak D, Martinelli G, Hofmann W, Koeffler P, Jumaa H, Müschen M. Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. Blood 2009, 114: 579-579. DOI: 10.1182/blood.v114.22.579.579.
- Leukemia Stem CellsMüschen M. Leukemia Stem Cells 2009, 281-294. DOI: 10.1007/978-90-481-3040-5_13.
- V(D)J RecombinationMüschen M. V(D)J Recombination 2009, 3160-3164. DOI: 10.1007/978-3-540-47648-1_6171.
- Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1Trageser D, Duy C, Klemm L, Gruber T, Nahar R, Park E, Kim Y, Groffen J, Heisterkamp N, Hofmann W, Martinelli G, Williams R, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1 Blood 2008, 112: 15-15. DOI: 10.1182/blood.v112.11.15.15.
- Obesity Accelerates T-Cell Leukemia in a Spontaneous Mouse Model.Yun J, Klemm L, Behan J, Müschen M, Mittelman S. Obesity Accelerates T-Cell Leukemia in a Spontaneous Mouse Model. Blood 2008, 112: 1909-1909. DOI: 10.1182/blood.v112.11.1909.1909.
- The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression.Nahar R, Trageser D, Klemm L, Duy C, van Essen P, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jack H, Jumaa H, Muschen M. The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression. Blood 2008, 112: 1918-1918. DOI: 10.1182/blood.v112.11.1918.1918.
- Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALLJiang E, Yu M, Hsieh Y, DeLaTorre B, Kadavallore A, Scharman C, Park E, Yang A, Muschen M, Groffen J, Heisterkamp N, Kim Y. Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL Blood 2008, 112: 2922-2922. DOI: 10.1182/blood.v112.11.2922.2922.
- Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell ReceptorDuy C, Klemm L, Nahar R, van Essen P, Sprangers M, Kim Y, Park E, Martinelli G, Heisterkamp N, Hofmann W, Jumaa H, Muschen M. Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor Blood 2008, 112: 294-294. DOI: 10.1182/blood.v112.11.294.294.
- BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic LeukemiaDuy C, Yu J, Cerchietti L, Klemm L, Nahar R, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jumaa H, Melnick A, Ye B, Muschen M. BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia Blood 2008, 112: 295-295. DOI: 10.1182/blood.v112.11.295.295.
- Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic HypermutationKlemm L, Duy C, Feldhahn N, Groffen J, Kim Y, Hofmann W, Jumaa H, Lieber M, Casellas R, Muschen M. Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic Hypermutation Blood 2008, 112: 571-571. DOI: 10.1182/blood.v112.11.571.571.
- The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cellsMelchior K, Weiß J, Zaehres H, Kim Y, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells Biological Chemistry 2008, 0: 080808064026415-22. DOI: 10.1515/bc.2008.108_bchm.just-accepted.
- PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia.Klemm L, Feldhahn N, Hoffmann T, Hofmann W, Jumaa H, Muschen M. PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia. Blood 2007, 110: 1005-1005. DOI: 10.1182/blood.v110.11.1005.1005.
- Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1.Trageser D, Klemm L, Herzog S, Kim Y, Duy C, Hofmann W, Groffen J, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1. Blood 2007, 110: 2795-2795. DOI: 10.1182/blood.v110.11.2795.2795.
- The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells.Duy C, de Alboran I, Jumaa H, Muschen M. The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells. Blood 2007, 110: 797-797. DOI: 10.1182/blood.v110.11.797.797.
- Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.Kim Y, Park E, Lorentzen C, De La Torre B, Hsieh Y, Whang H, Klemm L, Nguyen C, McMillan M, Teo J, Muschen M, Kahn M. Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia. Blood 2007, 110: 1596-1596. DOI: 10.1182/blood.v110.11.1596.1596.
- Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cellsFeldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells Journal Of Experimental Medicine 2007, 204: 1157-1166. PMID: 17485517, PMCID: PMC2118573, DOI: 10.1084/jem.20062662.
- Activation-Induced Cytidine Deaminase Acts as a Mutator in BCR-ABL1-Transformed Acute Lymphoblastic Leukemia Cells.Feldhahn N, Klein F, Hofmann W, Rowley J, Jumaa H, Müschen M. Activation-Induced Cytidine Deaminase Acts as a Mutator in BCR-ABL1-Transformed Acute Lymphoblastic Leukemia Cells. Blood 2006, 108: 640-640. DOI: 10.1182/blood.v108.11.640.640.
- Immunoglobulin class‐switch recombination occurs in mantle cell lymphomasKlapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen N, Greeve J, Parwaresch R. Immunoglobulin class‐switch recombination occurs in mantle cell lymphomas The Journal Of Pathology 2006, 209: 250-257. PMID: 16508921, DOI: 10.1002/path.1961.
- SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cellsSprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells Oncogene 2006, 25: 5180-5186. PMID: 16636677, DOI: 10.1038/sj.onc.1209520.
- The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cellsSprangers M, Feldhahn N, Herzog S, Hansmann M, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells Oncogene 2006, 25: 5056-5062. PMID: 16568084, DOI: 10.1038/sj.onc.1209510.
- BCR–ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cellsKlein F, Feldhahn N, Herzog S, Sprangers M, Mooster J, Jumaa H, Müschen M. BCR–ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells Oncogene 2005, 25: 1118-1124. PMID: 16205638, DOI: 10.1038/sj.onc.1209133.
- Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cellsFeldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cells Journal Of Experimental Medicine 2005, 201: 1837-1852. PMID: 15939795, PMCID: PMC2213268, DOI: 10.1084/jem.20042101.
- The BCR-ABL1 Kinase Interferes with Pre-B Cell Receptor Signal Transduction in B Cell Precursor Leukemia Cells.Klein F, Feldhahn N, Wernet P, Müschen M. The BCR-ABL1 Kinase Interferes with Pre-B Cell Receptor Signal Transduction in B Cell Precursor Leukemia Cells. Blood 2004, 104: 1894-1894. DOI: 10.1182/blood.v104.11.1894.1894.
- Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion and IGL Gene Rearrangement.Klein F, Feldhahn N, Mooster J, Wernet P, Müschen M. Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion and IGL Gene Rearrangement. Blood 2004, 104: 315-315. DOI: 10.1182/blood.v104.11.315.315.
- A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation PotentialKögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg R, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller H, Zanjani E, Wernet P. A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential Journal Of Experimental Medicine 2004, 200: 123-135. PMID: 15263023, PMCID: PMC2212008, DOI: 10.1084/jem.20040440.
- Aberrantly regulated genes in TEL/AML1 positive leukaemiaHentschel U, Feldhahn N, Berthold F, Müschen M, Fischer M. Aberrantly regulated genes in TEL/AML1 positive leukaemia Klinische Pädiatrie 2004, 216 DOI: 10.1055/s-2004-828574.
- The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia CellsKlein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia Cells Journal Of Experimental Medicine 2004, 199: 673-685. PMID: 14993251, PMCID: PMC2213306, DOI: 10.1084/jem.20031637.
- CD95 ligand expression mediates immune escape in breast cancerMoers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression mediates immune escape in breast cancer Breast Cancer Research 2001, 3: a76. PMCID: PMC3300589, DOI: 10.1186/bcr406.
- Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 geneMoers C, Müschen M, Beckmann M, Mallmann P. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene Breast Cancer Research 2001, 3: a77. PMCID: PMC3300590, DOI: 10.1186/bcr407.
- CD95 ligand expression in dedifferentiated breast cancerMoers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression in dedifferentiated breast cancer Breast Cancer Research 2001, 3: a75. PMCID: PMC3300588, DOI: 10.1186/bcr405.
- Resistance to CD95‐mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 geneMüschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann M. Resistance to CD95‐mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene International Journal Of Cancer 2001, 92: 309-310. PMID: 11291062, DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1188>3.0.co;2-5.
- Molecular Single-Cell Analysis of Hodgkin- and Reed-Sternberg Cells Harboring Unmutated Immunoglobulin Variable Region GenesMüschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann M. Molecular Single-Cell Analysis of Hodgkin- and Reed-Sternberg Cells Harboring Unmutated Immunoglobulin Variable Region Genes Laboratory Investigation 2001, 81: 289-295. PMID: 11310822, DOI: 10.1038/labinvest.3780237.
- Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Research 2001, 61: 2080-4. PMID: 11280769.
- Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusionsKüppers R, Bräuninger A, Müschen M, Distler V, Hansmann M, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions Blood 2001, 97: 818-821. PMID: 11157505, DOI: 10.1182/blood.v97.3.818.
- Somatic Mutation of the Cd95 Gene in Human B Cells as a Side-Effect of the Germinal Center ReactionMüschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic Mutation of the Cd95 Gene in Human B Cells as a Side-Effect of the Germinal Center Reaction Journal Of Experimental Medicine 2000, 192: 1833-1840. PMID: 11120779, PMCID: PMC2213498, DOI: 10.1084/jem.192.12.1833.
- Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.Müschen M, Re D, Bräuninger A, Wolf J, Hansmann M, Diehl V, Küppers R, Rajewsky K. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Research 2000, 60: 5640-3. PMID: 11059754.
- CD95 ligand expression as a criterion of malignant transformation in breast cancerMüschen M, Beckmann M. CD95 ligand expression as a criterion of malignant transformation in breast cancer The Journal Of Pathology 2000, 191: 468-469. PMID: 10918226, DOI: 10.1002/1096-9896(200008)191:4<468::aid-path647>3.0.co;2-j.
- Defining CD95 as a tumor suppressor geneMüschen M, Warskulat U, Beckmann M. Defining CD95 as a tumor suppressor gene Journal Of Molecular Medicine 2000, 78: 312-325. PMID: 11001528, DOI: 10.1007/s001090000112.
- Rare Occurrence of Classical Hodgkin's Disease as a T Cell LymphomaMüschen M, Rajewsky K, Bräuninger A, Baur A, Oudejans J, Roers A, Hansmann M, Küppers R. Rare Occurrence of Classical Hodgkin's Disease as a T Cell Lymphoma Journal Of Experimental Medicine 2000, 191: 387-394. PMID: 10637283, PMCID: PMC2195757, DOI: 10.1084/jem.191.2.387.
- CD95 ligand expression as a mechanism of immune escape in breast cancerMüschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann M. CD95 ligand expression as a mechanism of immune escape in breast cancer Immunology 2000, 99: 69-77. PMID: 10651943, PMCID: PMC2327134, DOI: 10.1046/j.1365-2567.2000.00921.x.
- CD95 ligand expression in dedifferentiated breast cancerMüschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann M, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer The Journal Of Pathology 1999, 189: 378-386. PMID: 10547600, DOI: 10.1002/(sici)1096-9896(199911)189:3<378::aid-path439>3.0.co;2-d.
- Involvement of Soluble CD95 in Churg-Strauss SyndromeMüschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of Soluble CD95 in Churg-Strauss Syndrome American Journal Of Pathology 1999, 155: 915-925. PMID: 10487849, PMCID: PMC1866905, DOI: 10.1016/s0002-9440(10)65191-7.
- Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulationMüschen M, Warskulat U, Peters-Regehr T, Bode J, Kubitz R, Häussinger D. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation Gastroenterology 1999, 116: 666-677. PMID: 10029626, DOI: 10.1016/s0016-5085(99)70189-7.
- Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatinMoers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann M, Häussinger D. Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin International Journal Of Cancer 1999, 80: 564-572. PMID: 9935158, DOI: 10.1002/(sici)1097-0215(19990209)80:4<564::aid-ijc14>3.0.co;2-x.
- A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou J, Cuturi M. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. Journal Of Clinical Investigation 1998, 102: 1920-1926. PMID: 9835616, PMCID: PMC509143, DOI: 10.1172/jci4221.
- Fas LIGAND, TUMOR NECROSIS FACTOR-α EXPRESSION, AND APOPTOSIS DURING ALLOGRAFT REJECTION AND TOLERANCEJosien R, Müschen M, Gilbert E, Douillard P, Heslan J, Soulillou J, Cuturi M. Fas LIGAND, TUMOR NECROSIS FACTOR-α EXPRESSION, AND APOPTOSIS DURING ALLOGRAFT REJECTION AND TOLERANCE Transplantation 1998, 66: 887-893. PMID: 9798699, DOI: 10.1097/00007890-199810150-00013.
- Deranged CD95 system in a case of Churg–Strauss vasculitisMüschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. Deranged CD95 system in a case of Churg–Strauss vasculitis Gastroenterology 1998, 114: 1351-1352. PMID: 9618660, DOI: 10.1016/s0016-5085(98)70458-5.
- CD95 ligand induced apoptosis as a mechanism of intrahepatic immunoregulationMüschen M, Warskulat U, Häussinger D. CD95 ligand induced apoptosis as a mechanism of intrahepatic immunoregulation Journal Of Hepatology 1998, 28: 47. DOI: 10.1016/s0168-8278(98)80395-4.
- Regulation of CD95 (APO‐1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cellsMüschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (APO‐1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells Hepatology 1998, 27: 200-208. PMID: 9425938, DOI: 10.1002/hep.510270131.
- Regulation of CD95 (Apo-1/Fas) Ligand and Receptor Expression in Human Embryonal Carcinoma Cells by Interferon γ and all-trans Retinoic AcidMüschen M, Warskulat U, Schmidt B, Schulz W, Häussinger D. Regulation of CD95 (Apo-1/Fas) Ligand and Receptor Expression in Human Embryonal Carcinoma Cells by Interferon γ and all-trans Retinoic Acid Biological Chemistry 1998, 379: 1083-1092. PMID: 9792441, DOI: 10.1515/bchm.1998.379.8-9.1083.
- Induction of Mouse Embryonal Carcinoma Cell Differentiation and Activation of the Retinoic Acid Receptor β2 Promoter by 1,25-Dihydroxyvitamin D3Müschen M, Sies H, Schulz W. Induction of Mouse Embryonal Carcinoma Cell Differentiation and Activation of the Retinoic Acid Receptor β2 Promoter by 1,25-Dihydroxyvitamin D3 Biological Chemistry 1996, 377: 703-710. PMID: 8960371, DOI: 10.1515/bchm3.1996.377.11.703.